Abstract
AbstractThis chapter describes briefly some scientific activities common to Richard P. Baum and Kalevi Kairemo. Both started with radioimmunodetection in late 1980s and ended up with radiomolecular precision oncology in 2020s. The author also had own interests which Richard Baum did not touch. The author worked some time with oligonucleotide radionuclide therapy (radionanotargeting) in the 1990s learning that it will be impossible in clinical practice. On the contrary, in spite of his own scepticism, intelligent multidisciplinary targeted nanoparticles could be constructed although being cumbersome. Here radiotheragnostic compounds will play major role. Additionally, some personal aspects are presented in order to honour Richard Baum’s achievements.
Publisher
Springer International Publishing
Reference32 articles.
1. Baum RP, Hertel A, Lorenz M, Schwarz A, Encke A, Hör G. 99Tcm-labelled anti-CEA monoclonal antibody for tumour immunoscintigraphy: first clinical results. Nucl Med Commun. 1989;10(5):345–52. Erratum in: Nucl Med Commun 1989 Oct;10(10):772–3.
2. Baum RP. Immunoscintigraphy as a diagnostic tool in pancreatic cancer. Hepatogastroenterology. 1989;36(6):459–61. Erratum in: Hepatogastroenterology 1990 Feb;37(1):154.
3. Baum RP, Adams S, Kiefer J, Niesen A, Knecht R, Howaldt HP, Hertel A, Adamietz IA, Sykes T, Boniface GR, et al. A novel technetium-99m labeled monoclonal antibody (174H.64) for staging head and neck cancer by immuno-SPECT. Acta Oncol. 1993;32(7–8):747–51.
4. Baum RP, Niesen A, Hertel A, Adams S, Kojouharoff G, Goldenberg DM, Hör G. Initial clinical results with technetium-99m-labeled LL2 monoclonal antibody fragment in the radioimmunodetection of B-cell lymphomas. Cancer. 1994;73(3 Suppl):896–9.
5. Baum RP, Brümmendorf TH. Radioimmunolocalization of primary and metastatic breast cancer. Q J Nucl Med. 1998;42(1):33–42. Review.